Gregory O'Gallagher on GLP-1s: what holds up and what doesn't

What did @gregoryogallagher actually say?

Gregory O'Gallagher says he's been using tirzepatide (he calls it 'Tezeptide') for six weeks, not to treat a disease, but to reduce hunger, stay in a caloric deficit effortlessly, and free up mental energy for other goals. He reports improved HbA1c, better insulin sensitivity, and says clients who struggled with deficits have broken through. His framing: this is 'the future of fitness.'

He's not subtle about the pitch. This is a wellness influencer using a prescription drug off-label for body composition optimization and positioning it as a lifestyle upgrade. That framing deserves serious scrutiny, not applause, before 290,000 viewers try to replicate it.

Does the science back this up?

On the core mechanism, yes, tirzepatide does reduce appetite and food intake, and the data is strong. On the broader lifestyle claims, it's more complicated.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 20.9% body weight reduction in adults with obesity over 72 weeks. Appetite suppression and reduced cravings are well-documented effects. The claim that it makes caloric deficits feel effortless has real biological support: the drug slows gastric emptying and acts on hypothalamic hunger circuits.

His claim about improved HbA1c and insulin sensitivity is also plausible. In people with prediabetes or metabolic dysfunction, weight loss and reduced caloric intake alone improve glycemic markers. Tirzepatide specifically has shown improvements in insulin sensitivity independent of weight loss (Frías et al., 2021, The Lancet). However, he offers zero baseline data, making his personal anecdote impossible to evaluate.

What did they get wrong (or right)?

He got the mechanism right. Tirzepatide reduces appetite. That part is not controversial.

What he got wrong, or at least badly undersold, is risk. Six weeks on a GLP-1/GIP agonist without mentioning nausea, vomiting, gastroparesis risk, pancreatitis, or the well-documented issue of lean mass loss alongside fat loss is a significant omission. Researchers including Wilding et al. (2022, Diabetes, Obesity and Metabolism) have noted that without adequate protein intake and resistance training, GLP-1-class drugs can accelerate muscle loss during caloric restriction.

His framing of this as 'the future of fitness' is also worth pushing back on. Using a prescription medication to manage hunger in metabolically healthy, lean individuals is a genuinely unsettled area. The SURMOUNT trials enrolled people with BMI over 27 with at least one weight-related comorbidity. Extrapolating those results to already-lean fitness enthusiasts is not supported by the literature.

One thing he did get right: the psychological burden of chronic dieting is real. Research on decision fatigue and dietary adherence (Baumeister et al., 2007, Current Directions in Psychological Science) supports the idea that reducing mental load around food decisions can improve outcomes. That part of his argument has a legitimate foundation.

What should you actually know?

Tirzepatide is a prescription drug approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) in specific populations. It is not approved or studied for use in lean, metabolically healthy individuals seeking marginal body composition improvements.

The off-label use he describes, low-dose tirzepatide in already-lean people, has no randomized controlled trial data behind it. That does not mean it has no effect. It means the risk-benefit calculation has not been done in that population. Side effects including nausea, vomiting, gallbladder disease, and potential thyroid C-cell effects (observed in rodent models, flagged by the FDA) are real considerations that his video ignores entirely.

If you're considering a GLP-1 or GIP agonist for weight management, that conversation belongs with a licensed clinician who can review your labs, health history, and actual goals, not a six-week TikTok experiment. The drug may be useful. The dosing, monitoring, and safety context matter enormously.